Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.40 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | Q9HBH1 | 1/20 | 0.39 | |
| ▸ | SSTR3 | P32745 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23425577 | 0.86 | KLKB1 (0.45) | SIRT2SIRT1TLR2KLKB1PDF | |
| SCHEMBL26283842 | 0.84 | CPB1 (0.49) | SIRT2SIRT1CPB1CPB2MMP3 | |
| SCHEMBL25052999 | 0.81 | SIRT2 (0.51) | SIRT2SIRT1SIRT3TLR2SIRT5 | |
| SCHEMBL26279273 | 0.81 | SIRT2 (0.44) | SIRT2SIRT1CPB1CPB2MMP3 | |
| SCHEMBL26281010 | 0.80 | CPB1 (0.47) | SIRT2SIRT1CPB1CPB2MMP3 | |
| SCHEMBL17090699 | 0.78 | KLKB1 (0.46) | SIRT2SIRT1MMP3KLKB1PDF | |
| SCHEMBL22452312 | 0.77 | SIRT2 (0.44) | SIRT2SIRT1CPB1CPB2MMP3 | |
| SCHEMBL26033430 | 0.76 | SIRT1 (0.45) | SIRT2SIRT1MMP3SIRT3KLKB1 | |
| SCHEMBL14950208 | 0.76 | FURIN (0.41) | SIRT2SIRT1CPB1CPB2MMP3 | |
| SCHEMBL14950214 | 0.76 | FURIN (0.41) | SIRT2SIRT1CPB1CPB2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | MABPLEX INTERNATIONAL CO., LTD (CN) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596693-B2 | Antibody-drug conjugates and uses thereof | DARS1, CD2, FCGR2A | SIRT2 2895/4885SIRT1 3268/4885CPB1 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.